VeriSIM Life Formalizes Research Collaboration with FDA/NCTR, Advancing the Next Generation of Mechanistic AI for Drug Development
Material Transfer Agreement establishes a formal framework for collaboration, reinforcing BIOiSIM's role as a scientifically defensible, mechanistically grounded AI platform designed for the rigor of translational drug development.
Drug development remains one of the most resource-intensive and failure-prone endeavors in modern science. Despite significant advances in artificial intelligence and computational chemistry, the fundamental translational gap between preclinical models and human clinical outcomes persists, contributing to late-stage failure rates that cost the industry hundreds of billions of dollars annually.
VeriSIM Life was founded to solve that problem. The company's core platform, BIOiSIM, is a hybrid mechanistic-AI system that integrates mechanistic quantitative models and machine learning into a unified translational framework spanning drug discovery, preclinical development, clinical optimization, and regulatory submission support.
VeriSIM Life has entered into a Material Transfer Agreement (MTA) with the FDA's National Center for Toxicological Research (FDA/NCTR), establishing a framework for ongoing scientific collaboration. The collaboration builds on prior peer reviewed work, including a 2025 co-authored publication demonstrating BIOiSIM's ability to predict drug induced liver injury. This agreement builds on VeriSIM’s ongoing scientific engagement with FDA/NCTR researchers and reinforces the rigor, transparency, and translational relevance of BIOiSIM’s mechanistically grounded AI system.
